Review of antifungal therapy, part II: Treatment rationale, including specific patient populations

References

• De Gentile L., Bouchara J. P., Le Clec'h C., et al. Prevalence of Candida ciferrii in elderly patients with trophic disorders of the legs. Mycopathologia 1995; 131: 99–102
   PubMedGoogle Scholar
• Contet‐Audonneau N., Schmutz J. L., Basile A. M., et al. A new agent of onychomycosis in elderly: Onychocola canadensis. Eur J Dermatol 1997; 7: 115–17
   Web of Science ®Google Scholar
• Seebacher C., Ulbricht H., Wörz K. Topical therapy of onychomycoses in geriatric patients. TW Dermatol 1993; 23: 434–8
   Google Scholar
• Gupta A. K., Skinner A. R. Onychomycosis in children: A brief overview with treatment strategies. Pediatr Dermatol 2004; 21: 74–9
   PubMed Web of Science ®Google Scholar
• Suarez S. New antifungal therapy for children. Adv Dermatol 1997; 12: 195–209
   PubMedGoogle Scholar
• Gupta A. K., Chang P., del Rosso J. Q., et al. Onychomycosis in children: Prevalence and management. Pediatr Dermatol 1998; 15: 464–71
   PubMed Web of Science ®Google Scholar
• Williams T. G., Hall M. Lack of interaction of oral terbinafine with oral contraceptives and healthy babies in a postmarketing surveillance study., Fifth Annual International Summit on Cutaneous Antifungal Therapy, Singapore; 1998. Abstract 67
   Google Scholar
• Gupta A. K., Taborda P., Taborda V., et al. Epidemiology and prevalence of onychomycosis in HIV‐positive individuals. Int J Dermatol 2000; 39: 746–53
   PubMed Web of Science ®Google Scholar
• Cribier B., Leiva Mena M., Rey D., et al. Nail changes in patients infected with immunodeficiency virus. A prospective controlled study. Arch Dermatol 1998; 134: 1216–20
   PubMedGoogle Scholar
• Conant M. A. The AIDS epidemic. J Am Acad Dermatol 1994; 31: S47–S50
   Google Scholar
• Ravnborg L., Baastrup N., Svejgaard E. Onychomycosis in HIV‐infected patients. Acta Derm Venereol 1998; 78: 151–2
   PubMedGoogle Scholar
• Goldman G. D., Bolognia J. L. HIV‐related skin disease: Managing fungal infections. J Respir Dis 1997; 18: 14–20
   Google Scholar
• Herranz P., Garcia J., De Lucas R., et al. Toenail onychomycosis in patients with acquired immune deficiency syndrome: Treatment with terbinafine. Br J Dermatol 1997; 139: 577–80
   Google Scholar
• Dompmartin D., Dompmartin A., Deluol A. M., et al. Onychomycosis and AIDS. Int J Dermatol 1990; 29: 337
   PubMed Web of Science ®Google Scholar
• Arrese J. E., Piérard‐Franchimont C., Piérard G. E. Fatal hyalohyphomycosis following Fusarium onychomycosis in an immunocompromised patient. Am J Dermatopathol 1996; 18: 196–8
   PubMed Web of Science ®Google Scholar
• Martino P., Gastaldi R., Raccah R., et al. Clinical patterns of Fusarium infections in immunocompromised patients. J Infect 1994; 28(Suppl 1)7–15
   PubMedGoogle Scholar
• Evans E. G. V. Causative pathogens in onychomycosis and the possibility of treatment resistance: A review. J Am Acad Dermatol 1998; 38: S32–S36
   Web of Science ®Google Scholar
• Chugh K. S., Sharma S. C., Singh V., et al. Spectrum of dermatological lesions in renal allograft recipient in a tropical environment. Dermatology 1994; 188: 108–12
   PubMedGoogle Scholar
• Gülec A. T., Demirbilek M., Seckin D., et al. Superficial fungal infection in 102 renal transplant recipients. A case control. J Am Acad Dermatol 2003; 49: 187–92
   PubMed Web of Science ®Google Scholar
• Virgili A., Zampino M. R., La Malfa V. Prevalence of superficial dermatomycoses in 73 renal transplant recipients. Dermatology 1999; 199: 31–4
   PubMed Web of Science ®Google Scholar
• Weglowska J., Szepietowski J., Walow B., et al. Onychomycosis in renal transplant recipient. Part II. Mycological aspects. Mikok Lek 2003; 10: 307–11
   Google Scholar
• Gupta A. K., Scher R. K., de Doncker P. Current management of onychomycosis. Dermatol Clin 1997; 15: 121–35
   PubMed Web of Science ®Google Scholar
• Denning D. W., Evans E. G., Kibbler C. C., et al. Fungal nail disease: A guide to good practice. BMJ 1995; 311: 1271–81
   Google Scholar
• Baran R., De Doncker P. Lateral edge involvement indicates poor prognosis for treating onychomycosis with the new systemic antifungals. Acta Derm Venereol 1996; 73: 82–3
   Google Scholar
• Sommer S., Sheean‐Dare R. A., Goodfield M. J. D., Evans E. G. V. Prediction of outcome in the treatment of onychomycosis. Clin Exp Dermatol 2003; 28: 425–8
   PubMedGoogle Scholar
• Hay R. J. Chronic dermatophyte infections. Superficial fungal infections, J Verbov. MTP Press, LancasterUK 1986; 23–4
   Google Scholar
• Roberts D. T., Evans E. G. V. Subungual dermatophytoma complicating dermatophyte onychomycosis. Br J Dermatol 1998; 138: 189–90
   PubMed Web of Science ®Google Scholar
• Frederiksson T. The pros and cons of an oral treatment of dermatomycosis. Dermatologica 1984; 169(Suppl 1)67–8
   PubMedGoogle Scholar
• Epstein E. How often does oral treatment of toenail onychomycosis produce a disease‐free nail? An analysis of published data. Arch Dermatol 1998; 134: 1551–4
   PubMedGoogle Scholar
• Nolting S. Onychomycosis. New approaches in therapy. Proceedings of the 19th World Congress of Dermatology, Sydney. 1997; 12
   Google Scholar
• Ghannoum M. A. Future of antimycotic therapy. Dermatol Ther 1997; 3: 104–11
   Google Scholar
• Polak‐Wyss A. Mechanism of action of antifungals and combination therapy. J Eur Acad Dermatol Venereol 1995; 4(Suppl 1)511–16
   Google Scholar
• Olafsson J., Sigurgeirsson B., Baran R. Combination therapy for onychomycosis. Br J Dermatol 2003; 149(Suppl 64)15–18
   PubMedGoogle Scholar
• Gupta A. K., Fleckman P., Baran R. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J Am Acad Dermatol 2000; 43: S70–S80
   PubMed Web of Science ®Google Scholar
• Gupta AK and the Onychomycosis Combination Therapy Study Group. Ciclopirox topical solution, 8% combined with oral terbinafine to treat onychomycosis: A randomized, evaluator‐blinded study. J Drugs Dermatol 2005; 4: 481–5
   PubMedGoogle Scholar
• Kim H. C., Jung K. B., Shin D. H., et al. Comparison of compliance and cure rate of systemic antifungal therapy versus combination therapy with systemic and topical agent in toenail onychomycosis. Korean J Med Mycol 2002; 7: 35–41
   Google Scholar
• Baran R., Feuilhade M., Datry A., et al. A randomized trial of amorolfine 5% solution nail lacquer combined with oral terbinafine compared with terbinafine alone in the treatment of dermatophytic toenail onychomycosis affecting the nail region. Br J Dermatol 2000; 142: 1177
   PubMed Web of Science ®Google Scholar
• Baran E., Bochenski J., Duczkowski M., et al. Combination therapy for onychomycosis with amorolfine nail lacquer and oral antifungal agents. Mikol Lek 2003; 10: 79–83
   Google Scholar
• Yoon Y. H., An J. Y., Ro B. I. Experience of combination treatment of toenail onychomycosis with oral itraconazole and topical 5% amorolfine nail lacquer. Korean J Med Mycol 2004; 9: 159–65
   Google Scholar
• Lecha M., Alsina M., Torres M., et al. Amorolfine and itraconazole combination for severe toenail onychomycosis: Results of an open randomised trial in Spain. Br J Dermatol 2001; 145(Suppl 60)21–6
   PubMedGoogle Scholar
• Rigopoulos D., Katoulis A., Ioannides D., et al. A randomised trial of amorolfine 5% solution nail lacquer in association with itraconazole pulse therapy compared with itraconazole alone in the treatment of Candida fingernail onychomycosis. Br J Dermatol 2003; 149: 151
   PubMed Web of Science ®Google Scholar
• Sergeev Y., Sergeev A. Pulsed combination therapy: The new option for onychomycosis. Mycoses 2001; 44(Suppl 1)68
   Google Scholar
• Harman S., Ashbee H. R., Evans E. G. Testing of antifungal combinations against yeasts and dermatophytes. J Dermatol Treat 2004; 15: 104–7
   PubMedGoogle Scholar
• Gupta A. K., Konnikov N., Lynde C. W. Sequential pulse therapy with itraconazole and terbinafine to treat onychomycosis of the fingernails. J Dermatol Treat 2000; 11: 151–4
   Web of Science ®Google Scholar
• Gupta A. K., Lyde C. W., Konnikov N. Single‐blind, randomized, prospective study of sequential itraconazole and terbinafine pulse compared with terbinafine pulse for the treatment of toenail onychomycosis. J Am Acad Dermatol 2001; 44: 485–91
   PubMed Web of Science ®Google Scholar
• Gupta A. K., Del Rosso J. Q. An evaluation of intermittent therapy used to treat onychomycosis and other dermatomycoses with the oral antifungal agents. Int J Dermatol 2000; 39: 401–11
   PubMed Web of Science ®Google Scholar
• Tausch I., Bräutigam M., Weiding G. Evaluation of 6 weeks treatment of terbinafine in tinea unguium in a double‐blind trial comparing 6 and 12 weeks therapy. Br J Dermatol 1997; 136: 737–42
   PubMed Web of Science ®Google Scholar
• Watson A., Marley J., Ellis D., et al. Terbinafine in onychomycosis of the toenail: A novel treatment protocol. J Am Acad Dermatol 1995; 33: 775–9
   PubMed Web of Science ®Google Scholar
• Haneke E., Ring J., Abeck D. Efficacy of itraconazole pulse treatment in onychomycosis. HGZ Hautkr 1997; 72: 737–40
   Google Scholar
• De Cuyper C. Therapeutic approach of recalcitrant toenail onychomycosis., Fifth International Summit on Cutaneous Antifungal Therapy, Singapore; 1998. Abstract 26
   Google Scholar
• Sigurgeirsson B., Paul C., Curran D., Evans E. G. V. Prognostic factors of mycological cure following treatment of onychomycosis with oral antifungal agents. Br J Dermatol 2002; 147: 1241–3
   PubMedGoogle Scholar
• Zaias N., Rebell G. The successful treatment of Trichophyton rubrum nail bed (distal subungual) onychomycosis with intermittent pulse‐dosed terbinafine. Arch Dermatol 2004; 140: 691–5
   PubMed Web of Science ®Google Scholar
• Di Chiacchio N., Kadunc B. V., De Almeida A. R. T., et al. Nail abrasion. J Cosmet Dermatol 2003; 2: 150–2
   PubMedGoogle Scholar
• Goodfield M. J. D., Evans E. G. V. Combined treatment with surgery and short duration oral antifungal therapy in patients with limited dermatophyte toenail infection. J Dermatol Treat 2000; 11: 259–62
   Web of Science ®Google Scholar
• Daniel C. R., Daniel M. P., Daniel C. M., et al. Chronic paronychia and onycholysis: A thirteen‐year experience. Cutis 1996; 58: 397–401
   PubMedGoogle Scholar
• Elewski B. E. Bacterial infection in a patient with onychomycosis. J Am Acad Dermatol 1997; 37: 493–4
   PubMedGoogle Scholar
• Tosti A., Piraccini B. M. Paronychia. Contact urticaria syndrome, S Amin, H Maibach. CRS Press, Boca Raton, FL 1997; 276–8
   Google Scholar
• Baran R., Hay R., Perrin Ch. Superficial white onychomycosis revisited. J Eur Acad Dermatol Venereol 2004; 18: 569–71
   PubMed Web of Science ®Google Scholar
• Ellis D. H., Marley J. E., Watson A. B. Significance of non‐dermatophyte moulds and yeasts in onychomycosis. Dermatology 1997; 194(Suppl 1)40–2
   PubMedGoogle Scholar
• Arenas R., Dominguez‐Cherit J., Fernandez L. Open randomized comparison of itraconazole versus terbinafine in onychomycosis. Int J Dermatol 1995; 34: 138–43
   PubMedGoogle Scholar
• Baran R. Nail fungal infections and treatment. Hand Clin 2002; 18: 625–8
   PubMed Web of Science ®Google Scholar
• Gupta A. K., Baran R., Summerbell R. Onychomycosis: Strategies to improve efficacy and reduce recurrence. J Eur Acad Dermatol Venereol 2002; 16: 579–86
   PubMed Web of Science ®Google Scholar
• Shuster S., Baran R. Recurrence of fungal nail disease and the dissociation of relapse from re‐infection. Acta Derm Venereol 2001; 81: 154–5
   PubMedGoogle Scholar
• Ogawa H., Summerbell R. C., Clemons K. V., et al. Dermatophytes and host defence in cutaneous mycoses. Med Mycol 1998; 36: 166–73
   PubMed Web of Science ®Google Scholar
• Woodfolk J. A., Platts‐Mills T. A. The immune response to dermatophytes. Res Immunol 1998; 149: 436–45
   PubMedGoogle Scholar
• Wagner D. K., Sohnle P. G. Cutaneous defenses against dermatophytes and yeasts. Clin Microbiol Rev 1995; 8: 317–35
   PubMed Web of Science ®Google Scholar
• Jones H. E. Cell‐mediated immunity in the immunopathogenesis of dermatophytosis. Acta Derm Venereol 1986, Suppl 121: 73–83
   PubMedGoogle Scholar
• Jones H. E. Factors involved in producing a sustained experimental dermatophyte infection (Trichophyton mentagrophytes). Cutis 2001; 67: 18–19
   PubMedGoogle Scholar
• Svejgaard E. Humoral antibody responses in the immunopathogenesis of dermatophytosis. Acta Derm Venereol 1986; 121(Suppl)73–83
   Google Scholar
• Kaaman T. Cell‐mediated reactivity in dermatophytosis: Differences in skin responses to purified Trichophyton in tinea pedis and tinea cruris. Acta Derm Venereol 1981; 61: 119–23
   PubMedGoogle Scholar
• Dahl M. V., Grando S. A. Chronic dermatophytosis: What is special about Trichophyton rubrum?. Adv Dermatol 1994; 9: 97–109
   PubMedGoogle Scholar
• Dahl M. V. Dermatophytosis and the immune response. J Am Acad Dermatol 1994; 31: S34–S41
   Web of Science ®Google Scholar
• Zaias N., Rebell G. Chronic dermatophytosis caused by Trichophyton rubrum. J Am Acad Dermatol 1996; 35: S17–S20
   Google Scholar
• Artis W. M., Jones H. E. The effect of human lymphokine on the growth of Trichophyton mentagrophytes. J Invest Dermatol 1982; 74: 131–4
   Google Scholar
• Poulain D., Tronchin G., Vernes A., Delabre M., Biguet J. Experimental study of resistance to infection by Trichophyton mentagrophytes: Demonstration of memory skin cells. J Invest Dermatol 1982; 74: 205–9
   Google Scholar
• Kaaman T. Dermatophyte antigens and cell‐mediated immunity in dermatophytosis. Curr Top Med Mycol 1985; 1: 117–34
   PubMedGoogle Scholar
• Hernandez A. D., Reece R. E., Zucker A. H. Trichophyton mentagrophytes spores differ from mycelia in the ability to induce pustules and activate complement. J Invest Dermatol 1986; 87: 683–7
   PubMedGoogle Scholar
• Ninomiya J., Ide M., Ito Y., Takiuchi I. Experimental penetration of Trichophyton mentagrophytes into the human stratum corneum. Mycopathologia 1998; 141: 153–7
   PubMedGoogle Scholar
• Jones H. E. Immune response and host resistance of humans to dermatophyte infection. J Am Acad Dermatol 1993; 28: S12–S18
   PubMed Web of Science ®Google Scholar
• Galitz J., Schein J. R. Symptom improvement in patients with onychomycosis receiving oral antifungal therapy. South Med J 2002; 95: 1359–60
   PubMedGoogle Scholar
• Maleszka R., Adamski Z., Dworacki G. Evaluation of lymphocytic subpopulations and natural killers in peripheral blood of patients treated for dermatophyte onychomycosis. Mycoses 2001; 44: 487–92
   PubMedGoogle Scholar
• Maleszka R. Enzymatic activity of dermatophytes in various forms of onychomycosis. Mikol Lek 1999; 6: 77–83
   Google Scholar
• De Doncker P., Degreef H., André J., Pierard G. Why are some with onychomycosis still not responding to the newer antifungal agents?, Orlando, AAD; 1998. Poster 187
   Google Scholar